<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01804400</url>
  </required_header>
  <id_info>
    <org_study_id>CQAW039A2212</org_study_id>
    <secondary_id>2012-001389-14</secondary_id>
    <nct_id>NCT01804400</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Three-period Incomplete Cross Over Study to Compare the Efficacy of QAW039 Alone and in Combination With Montelukast in Patients With Allergic Rhinitis Using an Environmental Exposure Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of QAW039 alone and in combination with
      Montelukast in patients with allergic rhinitis (hay fever) using an environmental exposure
      chamber.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Nasal Symptom Score from baseline at 14 days</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Total Nasal Symptom Score (TNSS) averaged over the last two hours (2-4h) of exposure following 14 days treatment with QAW039 and/or Montelukast or matched placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Ocular Symptom score from Baseline at 14 days</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Total Ocular Symptom Score (TOSS), defined as the sum of ocular symptoms of eye tearing, itching, watery eyes and redness, each of which is scored on a scale from 0 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nasal Flow from baseline at 14 days</measure>
    <time_frame>Prior to, and every 60 min during allergen exposure period</time_frame>
    <description>Measured using rhinomanometry Flow rates at 150 Pa will be obtained separately for the right and left nostrils (cm^3/second). The sum of the flow rates of both nostrils will be calculated from the two measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nasal excretion weight from baseline at 14 days</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Total weight of tissues (before and after use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 Second (FEV1) from baseline at 14 days</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Change in FEV1 from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC) from baseline at 14 days</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Change in FVC from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1/FVC at from baseline at 14 days</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Change in FEV1/FVC from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration maximum (Cmax)</measure>
    <time_frame>Day 1-14</time_frame>
    <description>Determined at steady state in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Minimum (Cmin)</measure>
    <time_frame>Day 1-14</time_frame>
    <description>Determined at steady state in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Average (Cav)</measure>
    <time_frame>Day 1-14</time_frame>
    <description>Determined at steady state in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax)</measure>
    <time_frame>Day 1-14</time_frame>
    <description>Determined at steady state in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUCtau)</measure>
    <time_frame>Day 1-14</time_frame>
    <description>Determined at steady state in plasma</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>QAW039 + Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QAW039 Once a day (q.d.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QAW039 Twice a day (b.i.d.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAW039</intervention_name>
    <arm_group_label>QAW039 + Montelukast</arm_group_label>
    <arm_group_label>QAW039 Once a day (q.d.)</arm_group_label>
    <arm_group_label>QAW039 Twice a day (b.i.d.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <arm_group_label>QAW039 + Montelukast</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>QAW039 + Montelukast</arm_group_label>
    <arm_group_label>QAW039 Once a day (q.d.)</arm_group_label>
    <arm_group_label>QAW039 Twice a day (b.i.d.)</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18-65 years inclusive, with a clinical history of intermittent
             allergic rhinitis with seasonal onset and offset of nasal allergy symptoms during each
             of the last two grass pollen allergy seasons.

          -  A positive skin prick test at Visit 1 to dactylis glomerata with a wheal diameter
             equal to or greater than 3 mm and a negative control with a wheal diameter of zero. A
             positive skin prick test within 12 months prior to Visit 1 is also acceptable.

          -  FEV1 measured by spirometry must be ≥80% of their predicted value at screening. If the
             patient does not achieve ≥80% of their predicted value this may be repeated prior to
             the EEC challenge at visit 2.

          -  TNSS score ≥6 on at least one assessment during the 2h EEC challenge at Screening.

        Exclusion Criteria:

          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer; or longer if required by local
             regulations, and for any other limitation of participation in an investigational trial
             based on local regulations.

          -  Pregnant or nursing (lactating) women,

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using effective methods of contraception during
             dosing of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=12683</url>
    <description>Results for CQAW039A2212 from the Novartis Clinical Trials Website</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2012</study_first_submitted>
  <study_first_submitted_qc>March 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2013</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Indoleacetic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

